We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intec Parent Inc | NASDAQ:NTEC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.63 | 9.71 | 9.90 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT of 1934
For the month of November 2018
001-37521
(Commission File Number)
INTEC PHARMA LTD.
(Translation of registrant’s name into English)
12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel
(+972) (2) 586-4657
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________
EXPLANATORY NOTE
Intec Pharma Ltd. (the “Company”) hereby furnishes the following documents:
i. | Notice and Proxy Statement with respect to the Company’s special general meeting of the shareholders to be held on December 20, 2018, describing the proposal to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting; and |
ii. | a Proxy Card whereby holders of Company’s shares may vote at the meeting without attending in person. |
The Notice and Proxy Statement is furnished with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K as Exhibit 99.2, both of which are incorporated by reference into the Company’s registration statements on Form S-8 (File Nos. 333-209700, No. 333-212801, No. 333-222217 and No. 333-227027 ).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INTEC PHARMA LTD. | ||
By: | /s/ Nir Sassi | |
Name: Nir Sassi | ||
Title: Chief Financial Officer | ||
Date: November 27, 2018 |
EXHIBIT INDEX
1 Year Intec Parent Chart |
1 Month Intec Parent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions